Marshall Wace, LLP Eagle Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

A detailed history of Marshall Wace, LLP transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 257,469 shares of EGRX stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

257,469

Previous 143,826 79.01%

Holding current value

$1.35 Million

Previous $752,000 79.39%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.26 - $6.51 $484,119 - $739,815	113,643 Added 79.01%	257,469 $1.35 Million
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $665,914 - $2.19 Million	143,826 New	143,826 $752,000
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $1.27 Million - $1.73 Million	50,691 Added 331.83%	65,967 $1.87 Million
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $381,594 - $607,526	15,276 New	15,276 $446,000
Q2 2021 Aug 13, 2021	SELL	$36.86 - $44.5 $864,330 - $1.04 Million	-23,449 Closed	0 $0

Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $945,463 - $1.2 Million	23,449 New	23,449 $979,000
Q4 2019 Feb 14, 2020	SELL	$54.32 - $64.31 $2.8 Million - $3.32 Million	-51,590 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$53.25 - $59.98 $854,130 - $962,079	16,040 Added 45.12%	51,590 $2.92 Million
Q2 2019 Aug 14, 2019	SELL	$46.61 - $58.45 $682,277 - $855,591	-14,638 Reduced 29.17%	35,550 $1.98 Million
Q1 2019 May 14, 2019	SELL	$38.66 - $51.82 $2.37 Million - $3.18 Million	-61,276 Reduced 54.97%	50,188 $2.53 Million
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $4.09 Million - $7.55 Million	111,464 New	111,464 $4.49 Million
Q2 2018 Aug 14, 2018	SELL	$51.25 - $76.62 $220,375 - $329,466	-4,300 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $224,287 - $287,498	4,300 New	4,300 $227,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

10.4M

Call Options Held

Put Options Held

36.3K

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $68.1M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Eagle Pharmaceuticals, Inc. Transaction History